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Regulation of collagen type IV genes is organ-specific: Evidence
from a canine model of Alport syndrome.
Background. Despite advances in knowledge about collagen
type IV at the protein level, little is known about expression of
its six a chains. X-linked Alport syndrome provides a system
to study collagen type IV gene expression within a setting of
disturbed protein synthesis. Mutations in the a5 chain result in
loss of the a3/a4/a5 and a1/a2/a5/a6 networks from the kidney,
with progressive renal disease.
Methods. We used a canine model of Alport syndrome to
measure expression of the six type IV collagen chains from
11 days to 71/2 months of age. We determined to what extent
message levels in kidney change over time, and what correla-
tion exists with clinical and pathologic changes in glomeruli, and
the primary mutation. The latter was evaluated by examining
testis, an organ normally containing the same collagen type IV
networks but uninvolved by disease.
Results. The a1 to a6 mRNAs were expressed at all time
points in normal canine kidney. By comparison to normal, in
Alport dog kidney, the a1 and a2 mRNAs were up-regulated
after 2 months of age, a3 and a4 mRNAs were down-regulated
by 2 months of age, and the a5 mRNA was almost undetectable
at any time. In testis, all mRNAs were expressed at comparable
levels in normal and affected dogs other than the a5 chain, which
was not expressed in affected testis.
Conclusion. Normal expression of collagen type IV is under
control mechanisms specific to each organ and to individual
chains. The altered expression in canine Alport syndrome is
not the direct result of the mutation, since these changes do
not occur in all organs nor are they present from birth. Instead,
collagen type IV expression is influenced by disease, with down-
regulation of a3 and a4 chains temporally related to the onset of
proteinuria, and up-regulation of a1 and a2 chains to glomeru-
losclerosis. This dysregulation of the a3 and a4 chains is unique
to this Alport model, and suggests an unidentified mechanism
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linking pathology with down-regulation of expression of these
two chains.
Alport syndrome is a hereditary disorder of type IV
collagen characterized by progressive nephropathy, oc-
ular abnormalities and high tone sensorineural deafness
[1–4]. About 80% of affected families show an X-linked
inheritance pattern and the remainder, autosomal. Pa-
tients have near normal kidney function at birth, which
deteriorates over time often leading to end-stage renal
disease (ESRD) by the end of the third decade, especially
in male patients with the X-linked form. The pathogen-
esis of Alport syndrome has been linked to mutations in
genes for type IV collagen. Type IV collagen is assem-
bled from a family of distinct a chains designated a1 to
a6, which are encoded by six different genes, COL4A1
to COL4A6, respectively (reviewed in [5, 6]). Over 300
mutations have been found in the COL4A5 gene in the
X-linked form of Alport syndrome [4, 7], leading to the
assembly of a glomerular basement membrane (GBM)
that is abnormal with respect to morphology and compo-
sition of type IV collagen a chains.
Recent work has shown the six collagen type IV
chains are organized into three distinct networks, a1/a2,
a3/a4/a5, and a1/a2/a5/a6 [6, 8–10]. Whereas basement
membranes of all organs contain the a1/a2 network, the
other networks are expressed in selected sites only, in
a distribution that is remarkably (although not 100%)
consistent across mammals, including humans, mice, and
dogs. The a3/a4/a5 network is present in mature GBM,
and the a1/a2/a5/a6 is present in Bowman’s capsule,
and around smooth muscle cells, but only rare basement
membranes such as the seminiferous tubule basement
membrane (STBM) contain all three networks [11–17].
In X-linked Alport syndrome, the GBM usually contains
only the a1 and a2 chains only and lacks the a3, a4, and a5
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chains [11, 12, 18, 19]. Similarly, Bowman’s capsule con-
tains the a1 and a2 chains only and lacks the a5 and a6
chains. The existence of the a3/a4/a5 and a1/a2/a5/a6
networks provides a plausible explanation for the ab-
sence of the a3 to a6 chains in X-linked Alport syndrome,
in that the a5 chain is critical to the assembly of both net-
works, and its absence prevents the assembly of the basic
monomers of these networks [8, 15]. Thus, starting with
immunohistochemical observations, there emerged from
continued studies at the protein level the discovery of
defined networks of collagen type IV and a better under-
standing of the abnormal GBM composition in Alport
syndrome.
The events happening at the transcriptional and trans-
lational levels are less well understood. Studies on the X-
linked model of Alport syndrome that occurs in a unique
family of Samoyed dogs have suggested that there are dis-
turbances at the mRNA level as well. The X-linked model
in this unique family of Samoyed dogs closely resembles
the human disease at the clinical, genetic, morphologic,
and immunohistochemical levels [20–23] and is caused by
a nonsense mutation in the COL4A5 gene [24]. This mu-
tation results in almost no mRNA for the a5 chain, and in
turn, loss of the a3/a4/a5 and a1/a2/a5/a6 networks from
the kidney [16]. Unexpectedly, the levels of the a3 and
a4 mRNAs are also reduced, implying the existence of
a mechanism coordinating the expression of the a3 and
a4 chains, perhaps tied into expression of the a5 chain,
which is virtually absent in this model [25]. Comparable
results have not been found in the few patients with Al-
port syndrome in whom the mRNA levels could be stud-
ied [26, 27] nor in a knockout mouse model [28]. Thus,
the Samoyed model becomes a unique source of infor-
mation about changes in mRNA levels for collagen type
IV and what mechanisms might underlie these changes.
To investigate this phenomenon further, we undertook a
time study of the expression of type IV collagen. We also
sought to differentiate the effects of disease from the ef-
fects of the mutation in the absence of disease. For the
former, we studied the kidney; for the latter, we needed
an organ in which all six collagen type IV chains were
expressed, but no disease occurred despite a COL4A5
mutation, and the testis was determined to be ideal for
this purpose. Finally, we studied expression of LMX1B,
the only transcription factor identified to date to regulate
the expression of the a4 chain [29].
METHODS
Immunohistochemistry
Expression of the a1/a2, a3/a4/a5, and a1/a2/a5/a6
networks was studied in the testis using normal dogs
and dogs with X-linked Alport syndrome. Sections were
stained according to methods previously published [16].
Normal testis (N = 4) and affected testis (N = 5) were
studied at 2 to 3 months of age. Antibodies used were
rat monoclonal antibodies to each of the six a-chains of
human type IV collagen. The specificity of these antibod-
ies has been previously reported [30]. Affected canine
kidneys were studied for the a1 and a2 chains of type
IV collagen at 1 week (N = 3), 11/2 months (N = 3), and
5 months (N = 3) of age.
Preparation of RNA from canine kidney and testis
Normal and affected dogs (paired male littermates)
were sacrificed at various time points from 11 days up
to 71/2 months of age and samples of tissue snap-frozen
in liquid nitrogen. Total RNA was prepared using Trizol
reagent (Gibco BRL, Burlington, Ontario, Canada), then
the mRNA recovered using the Straight A’s mRNA Iso-
lation System (Novagen, Madison, WI, USA). Samples
from 8 to 28 dogs were used for each Northern blot.
Northern blot analysis and densitometry
Electrophoresis and blotting of 1 to 1.5 lg samples of
mRNA prepared from normal and affected male canine
kidney and testis were done as previously described [24].
The probes for the a1 to a6 mRNAs were cDNAs for the
respective canine NC1 domains that were obtained using
nested polymerase chain reactions (PCR) as previously
described [24, 25]. All probes were labeled with [32P]-
deoxycytidimine triphosphate (dCTP) by random primer
synthesis. A probe for glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was used as a control for loading.
Each gel was run in duplicate. For a1 to a6 mRNAs, sam-
ples from 10 to 14 normal and 10 to 14 affected dogs were
used, depending on the individual a chain. For LMX1B
mRNA, samples from 10 normal and 10 affected dog kid-
neys and from eight normal and eight affected dog testes.
The intensities of the hybridization signals from the au-
toradiograms were integrated (Fluorchem 8000) (Alpha
Innotech/Packard, San Leandro, CA, USA) and plotted
over time. The values were normalized relative to the in-
tegrated density value obtained from the GAPDH tran-
script at each time point, in order to control for variations
in gel loading.
Generation of probes for LMX1B
By reverse transcription (RT)-PCR, the pairs of syn-
thetic oligonucleotide primers were constructed based
on sequences of human LMX1B [31] (GenBank acces-
sion number AF057135). The sequences for the LMX1B
primers were: primer for RT 5′-TCA GGA GGC GAA
GTA GGA-3′ (bp 1102-1119); external sense 5′-TGG
ACG GCA TCA AGA TGG-3′ (bp 5-23) and antisense
5′-CTC TGC ATG GAG TAG AG-3′ (bp 1084-1100);
and internal sense 5′-TGG CAC GAG GAG TGT TTG
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CA-3′ (bp 157-176) and antisense was the same as used
in external PCR.
The first round of PCR was performed using one tenth
of the RT reaction solution that had been synthesized
from 20 lg of total RNA and BRL SuperScript II RNaseH
Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA).
To this were added 200 ng of both external primers in
Perkin-Elmer PCR buffer (Perkin-Elmer Canada, Wood-
bridge, Canada) containing 1.5 mmol/L MgCl2 and 2 lL
10 mmol/L deoxynucleosidetriphosphate (dNTP) and
0.5 lL of AmpliTaq Gold (2.5 U) (Perkin-Elmer) to a
total volume of 100 lL. Samples were denatured at 95◦C
for 10 minutes and 35 cycles were carried out in a Perkin-
Elmer Cetus DNA Thermal Cycler. Each cycle consisted
of denaturation at 95◦C for 45 seconds, annealing at 55◦C
for 45 seconds, and extension at 72◦C for 11/2 minutes.
For the second round of PCR, a 1 lL aliquot of the first
PCR reaction mixture was amplified by the same method,
except using the internal primers.
Nucleotide sequencing
The amplified product was purified by Qiaex II Gel
Extraction Kit (Qiagen, Santa Clarita, CA, USA) accord-
ing to the manufacturer’s instructions. The PCR product
was subcloned into the TA cloning PCR vector (Invitro-
gen, San Diego, CA, USA), and then sequenced using
a Thermal Sequenase Fluorescent-labeled Primer Cycle
Sequencing Kit (Amersham, Oakville, Ontario) and a
Licor 4000L Sequencer (Lincoln, NE, USA).
RESULTS
Collagen networks in canine testis
In order to validate the use of testis for comparison
to kidney in terms of collagen type IV chain expression,
canine testis was first studied by immunohistochemistry.
It was important to establish that all chains of type IV
collagen were present, since this is not the case for all
mammals. For example, normal murine testis does not ex-
press the a6 chain [32]. Notwithstanding, normal canine
testis does expressed all six a chains in the seminiferous
tubule basement membrane (Fig. 1), whereas affected ca-
nine testis expressed only the a1 and a2 chains (results
not shown).
Northern analysis of a1 to a6 mRNA levels
in canine kidney
In normal and affected canine kidney, mRNAs for the
a1 to a6 chains were detectable at all time points exam-
ined between 11 days and 71/2 months (Fig. 2). The a1
and a2 mRNAs were expressed at comparable levels for
normal and affected canine kidney until approximately
3 months, at which time expression for both chains was
greater in the affected canine kidney and much more so
Fig. 1. Immunohistochemical staining of normal canine testis for the
six a chains of collagen type IV. All six chains are expressed in the
seminiferous tubule basement membrane (STBM).
by 5 months. Expression of the a3 and a4 chains was
highest in the first month of life and was equally high for
normal and affected canine kidney. After this time, there
was a decline in expression of both chains in both normal
and affected kidney. However, the decline was notably
greater in affected kidney, resulting in levels that were
approximately 25% of normal by 3 to 4 months. Expres-
sion of the a5 chain was highest in the first month of life
in normal canine kidney, declining thereafter. In affected
canine kidney, there was almost no expression of the a5
chain at any time. The a6 chain was also expressed at
its highest levels in the first month of life with a decline
thereafter. Expression was at approximately equivalent
levels in normal and affected canine kidney at all times.
Immunohistochemical staining for the a1 and a2 chains
in affected canine kidney
In younger affected male dogs, the staining pattern
was comparable to that reported previously [16], with
presence of both chains in mesangial regions and along
capillary loops. In older affected male dogs, there was
increased staining particularly in areas of glomeruloscle-
rosis (Fig. 3).
Northern analysis of a1 to a6 mRNA levels in canine testis
All chains except the a5 chain were expressed at ap-
proximately equivalent levels in normal and affected ca-
nine testis (Fig. 4). Expression of the a1 and a2 chains
showed a peak at around 3 months of age (i.e., 1 month
later than the kidney) and declined thereafter. There was
no increase in expression in older affected canine testis,
in contrast to what was observed in affected kidney. In
fact, by 7 months, mRNA levels were barely detectable.
The sizes of the mRNA signals were the same for both or-
gans, at 6.6, 6.1, and 5.5 kb for the a1 chain and 6.4 kb for
the a2 chain (results not shown), as has been reported
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Fig. 2. Densitometry graphs for expression of the 6 type IV collagen chains over time in normal (◦) and affected (•) canine kidney. For any given
chain, 10 to 14 normal and 10 to 14 affected dogs were used. Age is plotted in months along the x axis. The y axis reflects the intensity of the signal
for the respective a chain mRNA chains. Signal intensity is expressed as an integrated density value (IDV) normalized for variation in gel loading
relative to the expression of the housekeeping gene.
previously [25]. For the a3 and a4 chains in the testis,
there was little difference in mRNA levels between nor-
mal and affected dogs, in contrast to what was found for
the kidney. Expression peaked at 3 months of age, sim-
ilar to the a1 and a2 chains. The level of expression in
affected testis was roughly equivalent at all times. For the
a3 chain, a single band at ∼8 kb was seen as previously
reported for kidney [25]. For the a4 chain, two different
species were detected at ∼10 kb and ∼6 kb, in contrast
to the kidney in which only the ∼10 kb species was de-
tected at any time (results not shown) as previously re-
ported [25]. Expression of the 6 kb form also peaked at
3 months but was almost undetectable thereafter. The a5
chain followed a similar change in expression over time
for normal canine testis as did the a1 to a4 chains, with
the peak of expression at 3 months of age. No difference
in mRNA sizes was noted between testis and kidney; ma-
jor (6.7 kb) and minor (8.6 kb) transcripts were identi-
fied, as previously reported for kidney [24]. As seen with
affected canine kidney, almost no signal for a5 mRNA
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Fig. 3. Immunohistochemical staining for
the a1 and a2 chains of collagen type IV in af-
fected male canine kidney. There is increased
staining for both chains in older (5 months is
shown) affected male dogs (bottom row) com-
pared to younger (1.5 months is shown) (top
row). The most intense staining is in regions
of glomerulosclerosis.
was detectable in affected canine testis at any time stud-
ied. The a6 chain was expressed in testis similar to the
pattern noted for the a3 and a4 chains with the peak of
expression at around 3 months of age, but ∼30% lower in
affected testis. At other times, expression was essentially
the same in normal and affected testis. As previously re-
ported, there were two mRNAs detected at ∼7.3 kb and
∼6.5 kb in the kidney, [25], whereas in the testis, only the
6.5 kb mRNA was detected (results not shown).
Northern analysis of LMX1B expression in normal canine
kidney and testis
Recently, LMX1B, a transcription factor specifically
controlling transcription of the COL4A4 gene was iden-
tified [29]. We therefore sought to determine whether
expression of this gene was dysregulated in canine Al-
port syndrome and whether the changes in transcription
of the canine COL4A3 and COL4A4 genes could be ex-
plained on this basis. A probe of 965 bp was generated by
PCR. The sequence obtained for canine LMX1B (Gen-
Bank accession number AY215073) shares 95% identity
with the human sequence (GenBank accession number
AF057135) and also includes a 21 bp insertion of GGT
GAC CAC ATG AAC CCC TAT between bp 960 and
961 of human LMX1B [31]. The amino acid sequence
over this region of canine LMX1B is identical to the hu-
man sequence except for the seven additional residues
of GDHMNPY resulting from the 21 bp insertion. By
Northern analysis, a signal was detected at ∼6.2 kb in
both kidney and testis (Fig. 5). In normal kidney, LMX1B
was expressed from 11 days of age onward, peaking at
approximately 2 months of age and declining steadily af-
terward. The level of expression was similar in normal
and affected kidney, but with levels in affected kidney
∼20% higher at most times. The pattern of expression in
testis was different, with expression peaking in normal
testis around 5 months, compared to 3 months in affected
testis. As well, expression was higher in affected testis
(∼35% to 115% higher depending on the age of the dog)
until around 7 months when expression was at its lowest.
DISCUSSION
While the protein interactions of the six collagen type
IV chains are becoming understood, far less is known
about the expression of these chains and their regula-
tory factors. One approach is to study disease states, in
order to reveal perturbations from the normal that may
then provide clues to specific mechanisms. For collagen
type IV, the disease of Alport syndrome provides a sys-
tem for this type of approach. Human tissue samples are
difficult to obtain and study. Several animal models of
Alport syndrome exist, but each model varies in disease
manifestations and, hence, what mechanisms they might
reveal. For the purposes of this study, the Samoyed model
was selected, since this model is known to show a greater
degree of dysregulation of collagen type IV chains when
compared to human Alport kidney and kidney from other
canine and murine Alport models [14, 26–28, 33, 34].
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Fig. 4. Densitometry graphs for expression of the 6 type IV collagen chains over time in normal (◦) and affected (•) canine testis. For any given
chain, 10 normal and 10 affected dogs were used. Age is plotted in months along the x axis. The y axis represents the intensity of the signal [as
integrated density value (IDV)] for the respective a chain mRNAs.
Previous studies on the Samoyed model of X-linked
hereditary nephritis showed a down-regulation of the
mRNA levels for the a3 and a4 chains in the setting of
a COL4A5 nonsense mutation in which there is almost
no a5 mRNA produced [24], implying there might be a
mechanism acting at the transcriptional or translational
level coordinating the expression of the a3, a4, and a5
chains [25]. Support for coordination of expression for
the a3, a4, and a5 chains came from the observation that
GBM undergoes a “developmental switch” in type IV
collagen chain expression; as glomeruli mature, the a1
and a2 chains are replaced by the a3, a4, and a5 chains
[35]. The renal disease in Alport syndrome could then
be viewed as a failure of this developmental switch [36],
a phenomenon that was demonstrated in the Samoyed
model [16]. It remained to be shown in this model, how-
ever, that at the time of this switch, there was a coor-
dinated down-regulation of the a3 and a4 chains in the
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setting of a COL4A5 nonsense mutation. In the present
study we determined that, while a5 mRNA was nearly
absent as early as 11 days of age (and presumably congen-
ital), the mRNA levels for the a3 and a4 chains are rea-
sonably normal until around 2 months of age. This result
is compatible with two earlier observations in this animal
model: (1) the a3 chain could be detected in podocytes
up to one month of age, although never in the GBM [16]
and (2) the original report of a reduction in a3 and a4
mRNA levels was based on samples of kidney taken at
four months of age [25]. Similarly, the increase in the ex-
pression of the a1 and a2 chains noted in the present
study only became significantly increased after 4 months
of age, and therefore was not noted in that earlier study.
The observed changes in mRNA levels in the Samoyed
model of X-linked Alport syndrome have implications
relevant to human Alport syndrome. Since the a3 and a4
chains are initially produced, the fact that the a3/a4/a5
network is missing from birth in the GBM of affected
male dogs, indicates a failure at the protein assembly
level, secondary to the lack of a normal a5 chain. The
same mechanism also accounts for the missing a1/a2/a5/
a6 network in this model. The subsequent down-
regulation of the a3 and a4 chains reflects disease pro-
gression, as does the up-regulation of the a1 and a2 chains
seen in this model. Concurrently, there is increased depo-
sition of these latter two chains in glomeruli, a change that
was previously noted in human Alport kidney [37]. These
changes in expression begin at a time when glomeru-
losclerosis is starting in this animal model. The changes
are unrelated to the time at which the developmental
switch in GBM composition normally occurs (around
birth) and the time at which disease starts (around 1 to
2 months). The down-regulation of the a3 and a4 chains
corresponds more closely to the onset of proteinuria. It is
possible this abnormal state provides some signal to the
podocytes to down-regulate these two chains, since these
cells are the main source of the a3 and a4 chains for the
GBM [27]. One might envision a feedback mechanism,
in the setting where translated a3 and/or a4 chains are
unused, because there is no a5 chain available for trimer
formation. Excess cytoplasmic a3 and/or a4 chains, or a
fragment thereof, might act in a negative feedback loop
to decrease transcription of their corresponding genes.
Increased cytoplasmic a3 chain has been demonstrated
in podocytes of affected dogs early in the course of the
disease [16].
As Alport syndrome progresses, a number of other
changes in the kidney have been reported, reflecting pro-
gressive abnormalities of gene expression [38]. Glomeru-
lar proteins in addition to collagen type IV known to be
altered in Alport syndrome include structural proteins
such as laminin-2 and laminin-4 [39], collagens V and VI
[37], and integrin a1 [40], and proteins that affect the pro-
duction and degradation of basement membranes such as
transforming growth factor-b (TGF-b) [41] and metallo-
proteinases [38].
While in terms of Alport syndrome, the degree of dys-
regulation of collagen type IV in the Samoyed model may
be unique, we reasoned this same aspect of the model
would provide an advantage over other models to gain
greater insight into the regulation of collagen type IV in
the normal setting. Knowing that the level of transcrip-
tion of the COL4A1-COL4A4 genes changes as the renal
disease progresses in affected dogs, the question arises as
to whether these changes are organ-specific and more
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likely disease-related, or present also in nondiseased tis-
sues, thus more likely related to the actual mutation. In
order to address this question, we chose to study testis
in normal and affected dogs. The rationale was based on
the following: (1) testis is not known to be a site of dis-
ease in human or canine Alport syndrome; (2) whereas
basement membranes of all organs contain the a1 and a2
chains, the testis is one of the few sites that normally ex-
presses all 6 chains [11, 12, 15]; and (3) the seminiferous
tubule basement membrane in normal dogs is positive for
the a1 to a6 chains, whereas in affected dogs only the a1
and a2 chains are present. Nevertheless, we found that
the mRNAs for all six chains were expressed in normal
and affected canine testis, at comparable levels except
for the a5 chain as expected in the context of a COL4A5
nonsense mutation. The data from testis indicate that the
abnormalities of expression of the COL4A1-COL4A4
genes in canine Alport syndrome are kidney-specific, and
therefore likely related to the renal disease and not the
underlying COL4A5 mutation.
In terms of normal biology, the results indicate that
transcription of the COL4A3 and COL4A4 genes is un-
der separate control from the COL4A5 gene and that
control of transcription is at least partly tissue-specific.
Further evidence for this comes from the Northern blot
results in this study that identified messages of different
sizes for the same chain, depending on the tissue exam-
ined. An additional ∼6 kb band was found for the a4
chain in the testis, and an additional ∼7.3 kb band for
the a6 chain in the kidney. These were presumed to re-
flect alternate splicing, although no experimental work
to confirm this assumption was performed. Variant iso-
forms of the a3, a5 and a6 chains have been reported in
humans, and these are known to arise from alternative
splicing [42–44] or to the use of different transcriptional
start sites [45].
Tissue-specific regulation has been reported for the a5
and a6 chains in mice, related to specific DNA sequences
upstream of the COL4A5 and COL4A6 genes, respec-
tively [46]. Using transgenic mice, one DNA fragment
directed a6 chain expression in the upper gastrointesti-
nal tract (esophagus, stomach, duodenum) whereas two
other fragments resulted in a5 or a6 chain expression
that was limited to the esophagus. Thus, the basis for
tissue-specific control of the a3 and a4 chains may also
lie in specific sequences upstream of the COL4A3 and
COL4A4 genes. The mechanisms controlling transcrip-
tion of these two genes are poorly understood, although
it is known that both genes share a common promoter
region [47]. The only factor identified so far that con-
trols transcription of the COL4A4 gene is LMX1B [29].
This factor alone cannot account for the dysregulation of
the a3 and a4 chains in the Samoyed model, since there
was no striking difference in LMX1B expression between
normal and affected canine kidney despite differences in
a4 mRNA levels, and LMX1B expression was higher in
affected testis, where a4 mRNA levels were comparable
in normal and affected dogs.
A yet unanswered question is why a reduction in the a3
and a4 mRNAs has not been documented in humans or
other animal models of Alport syndrome. It is possible
this may be a later change in human Alport syndrome
as it is in canine Alport syndrome, and patients would
normally be biopsied for diagnostic purposes early in the
course of the disease. Another possible explanation is
that the genetic background of this family of dogs may
influence expression of these chains. Both the Samoyed
model and the Navasota canine model of X-linked Alport
syndrome [33, 48] result from a premature stop codon
in the COL4A5 gene and similar effects might be pre-
dicted; yet the disease in Navasota dogs has a later onset,
a slower progression to end-stage renal disease, and no
down-regulation of the a3 and a4 mRNAs. In COL4A3
knockout mouse models, the same mutation results in
different disease manifestations in the kidney, including
degrees of GBM splitting, severity of tubulointerstitial
changes, and the age at which ESRD occurred [49]. These
differences were related to the genetic backgrounds in the
strains of mice used to create the models, and compar-
isons between models led to the identification of regions
of the murine genome where modifier genes were likely
located. Modifier genes that affect collagen chain expres-
sion may also exist and such genes may be operational
in the Samoyed model. Further studies along this line of
investigation would be warranted.
Despite the great advances made in understanding col-
lagen type IV in the last few decades, still very little is
known about the expression of this protein that is present
in every organ of the body. Knowledge about normal biol-
ogy often comes from studying a situation in which there
is a disturbance of the normal. The Samoyed model for
Alport syndrome is one of the very few animal models in
which there is disturbed regulation of type IV collagen
expression. This model reveals that expression of colla-
gen type IV is individualized for specific tissues and for
individual a chains within a tissue, in terms of level of ex-
pression and, for some chains, sizes of mRNA. Moreover,
there must exist controlling systems that are disturbed by
disease processes, resulting for example in up-regulation
of some chains (a1 and a2) and down-regulation of others
(a3 and a4). The regulating factors are yet to be uncov-
ered, but these may also be important in the site-specific
distribution of the different collagen type IV networks
and regulation of the amount of extracellular matrix laid
down in specific sites. In this respect, the Samoyed model
serves as a valuable system for uncovering and exploring
the mechanisms that normally control collagen type IV
production.
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